128 related articles for article (PubMed ID: 21311410)
1. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
[TBL] [Abstract][Full Text] [Related]
2. Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia.
Cheng F; Cui Z; Li Q; Chen S; Li W; Zhang Y
Int Immunopharmacol; 2024 May; 133():112090. PubMed ID: 38640718
[TBL] [Abstract][Full Text] [Related]
3. Effect of genetic polymorphisms on the pharmacokinetics of gefitinib in healthy Chinese volunteers.
Chen YR; Yu X; Xu LM; Mei J; Tian ML; Xu M; Jin QY; Ye LB; Yang SX
Xenobiotica; 2024 Jan; 54(1):38-44. PubMed ID: 38085693
[TBL] [Abstract][Full Text] [Related]
4. ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib.
Wang Y; Sparidans RW; Potters S; Lebre MC; Beijnen JH; Schinkel AH
Pharmacol Res; 2021 Oct; 172():105850. PubMed ID: 34450308
[TBL] [Abstract][Full Text] [Related]
5. Association of
Asadov C; Karimova N; Hasanova A; Bayramov B; Shirinova A; Alimirzoyeva Z
Indian J Med Res; 2023 Aug; 158(2):151-160. PubMed ID: 37706370
[TBL] [Abstract][Full Text] [Related]
6. Ontogeny of Hepatic Drug Transporters as Quantified by LC-MS/MS Proteomics.
Prasad B; Gaedigk A; Vrana M; Gaedigk R; Leeder JS; Salphati L; Chu X; Xiao G; Hop C; Evers R; Gan L; Unadkat JD
Clin Pharmacol Ther; 2016 Oct; 100(4):362-70. PubMed ID: 27301780
[TBL] [Abstract][Full Text] [Related]
7. The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib.
Machova Polakova K; Albeer A; Polivkova V; Krutska M; Vlcanova K; Curik N; Fabarius A; Klamova H; Spiess B; Waller CF; Brümmendorf TH; Dengler J; Kunzmann V; Burchert A; Belohlavkova P; Mustjoki S; Faber E; Mayer J; Zackova D; Panayiotidis P; Richter J; Hjorth-Hansen H; Kamińska M; Płonka M; Szczepanek E; Szarejko M; Bober G; Hus I; Grzybowska-Izydorczyk O; Wasilewska E; Paczkowska E; Niesiobędzka-Krężel J; Giannopoulos K; Mahon FX; Sacha T; Saußele S; Pfirrmann M
Leukemia; 2024 Feb; 38(2):318-325. PubMed ID: 38129513
[TBL] [Abstract][Full Text] [Related]
8. Contribution of genetic polymorphism in
Ge Y; Bai H; Mazzocca A; Zhang J; Wang Z; Wu X
J Gastrointest Oncol; 2024 Apr; 15(2):577-584. PubMed ID: 38756645
[TBL] [Abstract][Full Text] [Related]
9. SLCO1B3 and SLCO2B1 genotypes, androgen deprivation therapy, and prostate cancer outcomes: a prospective cohort study and meta-analysis.
Rajanala SH; Plym A; Vaselkiv JB; Ebot EM; Matsoukas K; Lin Z; Chakraborty G; Markt SC; Penney KL; Lee GM; Mucci LA; Kantoff PW; Stopsack KH
Carcinogenesis; 2024 Feb; 45(1-2):35-44. PubMed ID: 37856781
[TBL] [Abstract][Full Text] [Related]
10. An in vivo hypoxia metagene identifies the novel hypoxia inducible factor target gene SLCO1B3.
Ramachandran A; Betts G; Bhana S; Helme G; Blick C; Moller-Levet C; Saunders E; Valentine H; Pepper S; Miller CJ; Buffa F; Harris AL; West CM
Eur J Cancer; 2013 May; 49(7):1741-51. PubMed ID: 23352438
[TBL] [Abstract][Full Text] [Related]
11. Detection of Extracellular Vesicle-Derived RNA as Potential Prostate Cancer Biomarkers: Role of Cancer-type SLCO1B3 and ABCC3.
Lee KY; Beatson EL; Knechel MA; Sommer ER; Napoli GC; Risdon EN; Leon AF; Depaz RD; Strope JD; Price DK; Chau CH; Figg WD
J Cancer; 2024; 15(3):615-622. PubMed ID: 38213719
[TBL] [Abstract][Full Text] [Related]
12. Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis.
Naidoo A; Ramsuran V; Chirehwa M; Denti P; McIlleron H; Naidoo K; Yende-Zuma N; Singh R; Ngcapu S; Chaudhry M; Pepper MS; Padayatchi N
Pharmacogenomics; 2018 Jan; 19(1):17-29. PubMed ID: 29210323
[TBL] [Abstract][Full Text] [Related]
13. Utilizing Pharmacogenomic Data for a Safer Use of Statins among the Emirati Population.
Alqasrawi MN; Al-Mahayri ZN; Alblooshi H; Alsafar H; Ali BR
Curr Vasc Pharmacol; 2024 Jan; ():e260124226224. PubMed ID: 38284696
[TBL] [Abstract][Full Text] [Related]
14. Dynamic induction of drug resistance through a stress-responsive enhancer in acute myeloid leukemia.
Williams MS; Somervaille TCP
Mol Cell Oncol; 2020; 7(2):1705730. PubMed ID: 32158919
[TBL] [Abstract][Full Text] [Related]
15. Effect of Genetic Variations in Drug-Metabolizing Enzymes and Drug Transporters on the Pharmacokinetics of Rifamycins: A Systematic Review.
Sileshi T; Mekonen G; Makonnen E; Aklillu E
Pharmgenomics Pers Med; 2022; 15():561-571. PubMed ID: 35693129
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia.
Yamakawa Y; Hamada A; Shuto T; Yuki M; Uchida T; Kai H; Kawaguchi T; Saito H
Clin Pharmacol Ther; 2011 Jul; 90(1):157-63. PubMed ID: 21633340
[TBL] [Abstract][Full Text] [Related]
17. Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients.
Chew SC; Sandanaraj E; Singh O; Chen X; Tan EH; Lim WT; Lee EJ; Chowbay B
Br J Clin Pharmacol; 2012 Apr; 73(4):606-18. PubMed ID: 21995462
[TBL] [Abstract][Full Text] [Related]
18. The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.
Chew SC; Singh O; Chen X; Ramasamy RD; Kulkarni T; Lee EJ; Tan EH; Lim WT; Chowbay B
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1471-8. PubMed ID: 21468756
[TBL] [Abstract][Full Text] [Related]
19. SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.
Singh O; Chan JY; Lin K; Heng CC; Chowbay B
PLoS One; 2012; 7(12):e51771. PubMed ID: 23272163
[TBL] [Abstract][Full Text] [Related]
20. CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients.
Barratt DT; Cox HK; Menelaou A; Yeung DT; White DL; Hughes TP; Somogyi AA
Clin Pharmacokinet; 2017 Aug; 56(8):977-985. PubMed ID: 27995529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
